Publication:
Hit identification against peptidyl-prolyl isomerase of Theileria annulata by combined virtual high-throughput screening and molecular dynamics simulation approach

dc.contributor.authorsSpahi, Sezen; Mutlu, Ozal; Sariyer, Emrah; Kocer, Sinem; Ugurel, Erennur; Turgut-Balik, Dilek
dc.date.accessioned2022-03-12T22:54:43Z
dc.date.accessioned2026-01-11T08:05:37Z
dc.date.available2022-03-12T22:54:43Z
dc.date.issued2020
dc.description.abstractTheileria annulata secretes peptidyl prolyl isomerase enzyme (TaPIN1) to manipulate the host cell oncogenic signaling pathway by disrupting the tumor suppressor F-box and WD repeat domain-containing 7 (FBW7) protein level leading to an increased level of c-Jun proto-oncogene. Buparvaquone is a hydroxynaphthoquinone antitheilerial drug and has been used to treat theileriosis. However, TaPIN1 contains the A53 P mutation that causes drug resistance. In this study, potential TaPIN1 inhibitors were investigated using a library of naphthoquinone derivatives. Comparative models of mutant (m) and wild type (wt) TaPIN1 were predicted and energy minimization was followed by structure validation. A naphthoquinone (hydroxynaphthalene-1,2-dione, hydroxynaphthalene-1,4-dione) and hydroxynaphthalene-2,3-dione library was screened by SchrOdinger Glide HTVS, SP and XP docking methodologies and the docked compounds were ranked by the Glide XP scoring function. The two highest ranked docked compounds Compound 1 (4-hydroxy-343,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-ylloxynaphthalene-1,2-dione) and Compound 2 (6-acety1-1,4,5,7,8-pentahydroxynaphthalene-2,3-dione) were used for further molecular dynamics (MD) simulation studies. The MD results showed that ligand Compound 1 was located in the active site of both mTaPIN1 and wtTaPIN1 and could be proposed as a potential inhibitor by acting as a substrate antagonist. However, ligand Compound 2 was displaced away from the binding pocket of wtTaPIN1 but was located near the active site binding pocket of mTaPIN1 suggesting that could be selectively evaluated as a potential inhibitor against the mTaPIN1. Compound 1 and Compound 2 ligands are potential inhibitors but Compound 2 is suggested as a better inhibitor for mTaPIN1. These ligands could also further evaluated as potential inhibitors against human peptidyl prolyl isomerase which causes cancer in humans by using the same mechanism as TaPIN1.
dc.identifier.doi10.1016/j.compbiolchem.2020.107398
dc.identifier.eissn1476-928X
dc.identifier.issn1476-9271
dc.identifier.pubmed33059132
dc.identifier.urihttps://hdl.handle.net/11424/236486
dc.identifier.wosWOS:000600544900013
dc.language.isoeng
dc.publisherELSEVIER SCI LTD
dc.relation.ispartofCOMPUTATIONAL BIOLOGY AND CHEMISTRY
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectTheileria annulata
dc.subjectPeptidyl prolyl isomerase
dc.subjectOnkogenic signalling patway
dc.subjectMolecular dynamics simulation
dc.subjectStructure-based drug design
dc.subjectDRUG DESIGN
dc.subjectTUMOR-SUPPRESSOR
dc.subjectDOCKING
dc.subjectBUPARVAQUONE
dc.subjectFBW7
dc.subjectVALIDATION
dc.subjectINFECTION
dc.subjectMODELS
dc.subjectSYSTEM
dc.subjectCATTLE
dc.titleHit identification against peptidyl-prolyl isomerase of Theileria annulata by combined virtual high-throughput screening and molecular dynamics simulation approach
dc.typearticle
dspace.entity.typePublication
oaire.citation.titleCOMPUTATIONAL BIOLOGY AND CHEMISTRY
oaire.citation.volume89

Files